虽然很多患者接受了疾病进展后的治疗（TBP），但这些患者的临床益处的程度和持续时间尚未完全量化。本研究收集了来自799例的黑色素瘤（n = 176），非小细胞肺癌（NSCLC）（n = 146），胃癌（GC）（n = 87），头颈鳞状细胞癌（HNSCC）（n = 112），透明细胞肾癌（ccRCC）（n = 51）和尿路上皮癌（UC）（n = 227）的TBP患者的数据。这些患者在RECIST v1.1标准下接受了Pembrolizumab治疗,并且这些患者的病灶直径之和在治疗后期进展阶段有30％的缩小（黑色素瘤24.4％，NSCLC 11.6％，GC 12.6％，HNSCC 8.9％，ccRCC 15.7％和UC 13.2％）。在治疗后期进展阶段，大多数患者的靶病灶动力学保持稳定（黑色素瘤64.8％，NSCLC 72.6％，GC 69.0％，HNSCC 75.9％，ccRCC 72.5％和UC 75.3％）。Pembrolizumab在治疗超过RECIST v1.1进展的一部分患者中产生了显著的疗效。版权所有 © 2023 Merck Sharp & Dohme LLC，美国Merck & Co.公司的子公司，位于美国新泽西， 雷威，作者保留所有权利。Elsevier Inc.保留所有权利。

While many patients are treated beyond progression (TBP), the magnitude and duration of clinical benefit in these patients have not been fully quantified. Data from 799 patients with melanoma (n = 176), non-small cell lung cancer (NSCLC; n = 146), gastric cancer (GC; n = 87), head and neck squamous cell carcinoma (HNSCC; n = 112), clear-cell renal cell carcinoma (ccRCC; n = 51), and urothelial carcinoma (UC; n = 227) TBP were included. Patients had received pembrolizumab beyond confirmed progressive disease (PD) per RECIST v1.1. A subset of patients displays a 30% reduction in the sum of lesion diameters in the post-progression period (melanoma 24.4%, NSCLC 11.6%, 12.6% GC, 8.9% HNSCC, 15.7% ccRCC, and 13.2% UC). Most patients show stable target lesion dynamics in the post-progression period (melanoma, 64.8%; NSCLC, 72.6%; GC, 69.0%, 75.9% HNSCC, 72.5% ccRCC, 75.3% UC). Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression.Copyright © 2023 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, The Author(s). Published by Elsevier Inc. All rights reserved.